Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.

Cibeira MT, de Larrea CF, Navarro A, Díaz T, Fuster D, Tovar N, Rosiñol L, Monzó M, Bladé J.

Leuk Res. 2011 Sep;35(9):1178-83. doi: 10.1016/j.leukres.2011.02.009. Epub 2011 Mar 23.

PMID:
21435719
2.

Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.

Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J.

Eur J Haematol. 2006 Dec;77(6):486-92. Epub 2006 Sep 15.

PMID:
16978238
3.

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, Varettoni M, Gay F, Morra E, Lazzarino M.

Leuk Res. 2009 Sep;33(9):e145-9. doi: 10.1016/j.leukres.2009.03.015. Epub 2009 Apr 16.

PMID:
19375164
4.

Thalidomide in refractory and relapsing multiple myeloma.

Bladé J, Esteve J, Rosiñol L, Perales M, Montoto S, Tuset M, Montserrat E.

Semin Oncol. 2001 Dec;28(6):588-92.

PMID:
11740814
5.

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U.

Ann Hematol. 2011 Oct;90(10):1173-81. doi: 10.1007/s00277-011-1194-3. Epub 2011 Feb 24.

PMID:
21347685
6.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

7.

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, Hellmann A, Wolska-Smolen T, Skotnicki A, Manko J; Polish Multiple Myeloma Study Group.

Haematologica. 2001 Apr;86(4):404-8.

8.

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R.

Clin Cancer Res. 2005 Aug 1;11(15):5504-14.

9.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC.

Blood. 2009 Jul 23;114(4):772-8. doi: 10.1182/blood-2008-12-196238. Epub 2009 May 26.

10.

Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.

Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F.

Bone Marrow Transplant. 2010 Aug;45(8):1316-24. doi: 10.1038/bmt.2009.335. Epub 2009 Dec 7.

PMID:
19966851
11.

Antitumor activity of thalidomide in refractory multiple myeloma.

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B.

N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.

12.

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H.

Blood. 2002 Sep 15;100(6):2263-5.

13.

Extramedullary multiple myeloma escapes the effect of thalidomide.

Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E.

Haematologica. 2004 Jul;89(7):832-6.

14.

[Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].

Ikebe T, Ogata M, Miyazaki M, Miyazaki Y, Ohtsuka E, Saburi Y, Goto K, Ikewaki J, Kohno K, Uno N, Imamura T, Akagi T, Kadota J.

Rinsho Ketsueki. 2010 Feb;51(2):114-21. Japanese.

PMID:
20379102
15.

[Thalidomide with or without dexamethasone for refractory multiple myeloma].

Boulin M, Blanchet F, Isambert N, Solary E, Solier S, Collin B, Pernot C, Durnet-Archeray MJ.

Therapie. 2002 Nov-Dec;57(6):524-9. French.

PMID:
12666259
16.

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.

Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ.

Int J Cancer. 2012 Sep 1;131(5):E636-42. doi: 10.1002/ijc.27387. Epub 2012 Jan 31.

17.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.

Blood. 2002 Nov 1;100(9):3063-7.

18.

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.

Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A.

Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.

PMID:
21334196
19.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
20.

Thalidomide in the treatment of multiple myeloma.

Rajkumar SV.

Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. Review.

PMID:
12113124

Supplemental Content

Support Center